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Over the past two decades, human embryonic stem cells (hESCs) have gained attention due to their pluripotent and proliferative
ability which enables production of almost all cell types in the human body in vitro and makes them an excellent tool to study
human embryogenesis and disease, as well as for drug discovery and cell transplantation therapies. Discovery of human-induced
pluripotent stem cells (hiPSCs) further expanded therapeutic applications of human pluripotent stem cells (PSCs). hPSCs
provide a stable and unlimited original cell source for producing suitable cells and tissues for downstream applications.
Therefore, engineering the environment in which these cells are grown, for stable and quality-controlled hPSC maintenance and
production, is one of the key factors governing the success of these applications. hPSCs are maintained in a particular niche
using specific cell culture components. Ideally, the culture should be free of xenobiotic components to render hPSCs suitable for
therapeutic applications. Substantial efforts have been put to identify effective components, and develop culture conditions and
protocols, for their large-scale expansion without compromising on quality. In this review, we discuss different media, their
components and functions, including specific requirements to maintain the pluripotent and proliferative ability of hPSCs.
Understanding the role of culture components would enable the development of appropriate conditions to promote large-scale,
quality-controlled expansion of hPSCs thereby increasing their potential applications.
1. Introduction
The quest to understand early embryonic development and
the differentiation into mature cell types dates back to the
early twentieth century when important experiments
described the development of testicular teratocarcinomas in
mice [1]. The observation that they were composed of undif-
ferentiated cells of germ cell origin and could give rise to
various types of differentiated cells sparked growing interest
in the subject. This was followed by the derivation of embry-
onal carcinoma cells (ECC) from murine teratocarcinomas,
which were cultured as embryoid bodies (EBs) and were mul-
tipotent [2]. The observation that even single ECCs obtained
from a teratocarcinoma had the capacity to grow indefinitely
and give rise to multiple cell types gave proof of the existence
of individual pluripotent stem cells and opened a unique
window into the study of early mammalian development
[3]. This discovery that ECCs could be derived from terato-
carcinomas, which are tumors induced by the transplanta-
tion of implantation-stage mouse embryos to extrauterine
sites in histocompatible hosts, inspired researchers to isolate
pluripotent cells directly from embryos itself, thus circum-
venting the need for generating/obtaining teratocarcinomas
for pluripotent stem cell isolation. Subsequently, the in vitro
culture of pluripotent cells was established by successfully
isolating the cells from the inner cell mass (ICM) of normal
preimplantation mouse blastocysts, and the term “embryonic
stem cell” (ESC) was coined [4, 5], thus distinguishing it from
teratocarcinoma-derived pluripotent ECCs. These pioneer-
ing experiments determined the optimal time point of isola-
tion of pluripotent ESCs from embryos and allowed the
development of appropriate culture conditions to maintain
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ESC lines in their undifferentiated state with indefinite
proliferation capacity [4, 6]. Further advances allowing
development of nonhuman primate ESC lines [7] eventually
led to the breakthrough establishment of hESC lines.
hESCs are derived from the ICM of preimplantation
blastocysts and can propagate and retain their pluripotency
when grown in proper culture conditions [4, 6]. These cells
show undifferentiated morphology, expression of pluripo-
tency markers, unlimited proliferation, and the potential to
differentiate into all three embryonic germ layers, even after
prolonged culture, while maintaining a normal karyotype.
These features have since then become the defining charac-
teristics of PSCs. Following hESCs, an important discovery
was the development of induced pluripotent stem cells
(iPSCs) by forced expression of transcription factors neces-
sary for reprogramming adult somatic cells into pluripotent
cells. This approach bypassed the need of embryos for
obtaining pluripotent stem cells, thereby resolving the ethical
concerns posed by hESC research [8].
The unique potential of hPSCs to self-renew in culture
and give rise to all somatic cell types in the embryo makes
them an exciting candidate for cell replacement therapy
(CRT) in various diseases such as degenerative disorders
and cancer, as well as offers limitless possibilities for under-
standing early development and establishing in vitro disease
models. Studies have demonstrated the capability of hPSCs
to differentiate into various cell types derived from ectoderm,
endoderm, and mesoderm, such as cardiomyocytes, neu-
rons, glia, hepatocytes, pancreatic islet cells, chondrocytes,
skeletal myocytes, adipocytes, and endothelial cells. Thus,
an unprecedented level of research is directed towards
elucidating the factors involved in regulating pluripotency
and differentiation. Knowledge of the same can be applied
towards recapitulating developmental stages and under-
standing the mechanisms underlying normal and diseased
states. It therefore has wide-ranging applications in advanc-
ing drug discovery, regenerative medicine, and gene therapy.
Furthermore, the use of hiPSCs opened up the possibility
of autologous CRT, moving us one step closer to the hope of
bringing stem cell therapies from the bench to bedside. It is
worth noting that hiPSCs share similar characteristics with
hESCs in terms of signaling mechanisms, and the culture sys-
tems for hiPSCs are similar to those used for hESCs as well.
Recent studies have shown that “pluripotency” exists in
different states, depending on the culture condition of hPSCs.
Amongst them, two functionally distinct stem cell states have
been identified, namely, “naïve” and “primed,” which are
similar to mouse ICM cells in preimplantation blastocyst
and epiblast layer cells in postimplantation blastocyst,
respectively [9–12]. Conventionally, hESC lines have been
derived and maintained in a pluripotent state resembling
the primed state in a mouse, represented by mouse epiblast
stem cells (mEpiSCs) [9, 11]. The same holds true for hiPSC
lines that have been reprogrammed using the method first
described by Takahashi et al. [8]. Since the discovery of the
two pluripotency states, it has been established that mouse
hESCs, which are in a “naïve” state, represent an earlier time
point than primed EpiSCs, in mouse embryonic development
[9–11]. Consequently, a huge body of research has been
aimed at optimizing culture conditions for each stage, and
recently, “naïve” hESCs have also been generated by toggling
conventional hESCs back from the “primed” state [13–15] or
by deriving new hESC lines from human six-cell to eight-
cell stage embryos, using naïve-state growth conditions
from the beginning of derivation itself [15]. Although
hPSCs in the naïve-state growth conditions are more
unstable than primed-state condition, these led to an
increased understanding of the pathways that are active/
inactive in vitro and how they can be manipulated by
growth factor and small molecule supplementation of
media, thus underscoring the importance of hPSC culture
media all the more.
The use of hPSCs in all downstream applications requires
the establishment of protocols that will allow large-scale,
cost-effective cultivation of cells, without compromising on
their quality. It is now well known that culture conditions
can affect several parameters, which are important to
evaluate for stem cell engineering applications, such as gene
correction or selection of genetically stable and highly plurip-
otent populations. Studies have shown how prolonged
culture of hPSCs can introduce spontaneous mutations or
genomic abnormalities, which invariably affect the purity,
consistency, potency, and functional capacity of hPSCs, as
they can bias or prime the cells away from their truly plurip-
otent state [16–21]. Suboptimal hPSC culture conditions can
therefore alter their identity and their compatibility with
downstream differentiation protocols. This can skew results
in research for disease modeling and drug-based studies
and also affect the final product that is to be used for trans-
plantation therapy. The possibility of such alterations in
hPSC quality and stability, introduced by culture media itself,
raises important concerns regarding the safety and risks asso-
ciated with using these cells for engineering and therapeutic
applications (Figure 1).
Since hPSCs are the most powerful and promising raw
material for cell engineering applications, understanding
and controlling the behavior of hPSCs by optimizing the
culture media, small molecules, growth factors, and micro-
environment, will allow the identification of appropriate
culture conditions for downstream applications such as
deriving specific cell types in CRT, drug discovery, and study
of human embryogenesis and disease mechanisms. This
review describes different media used to maintain hPSCs in
their pluripotent state, their components and functions, and
advancements in the development of appropriate conditions
to promote large-scale, quality-controlled expansion of
hPSCs thereby increasing their potential applications.
2. Evolution of an Adherent Culture
System for hPSCs
2.1. Traditional Culture System. The ICM cells, once isolated,
need to be placed on suitable appropriate extracellular matri-
ces (ECMs) and cultured in media that can support their
pluripotency and maintain self-renewal. Traditionally, the
blastocyst-derived cells were plated and serially propagated
on mouse embryonic fibroblasts (MEFs) that are mitotically
inactivated by mitomycin C treatment or gamma irradiation
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[6]. Studies that have analyzed fibroblast conditioned media
and decellularized matrices with mass spectrometry have
revealed that these feeder cells secrete essential growth fac-
tors, ECM components, and cytokines into the culture media,
which support hESC growth and proliferation, such as fibro-
blast growth factors (FGFs), transforming growth factor-β
(TGFβ), bone morphogenetic proteins (BMPs), Activin A,
laminin-511, laminin-binding integrins, vitronectin, heparan
sulphate proteoglycans, fibronectin, and collagen [22, 23].
However, several factors can affect the performance of
feeder layers, thereby affecting the secretion of factors and
deposition of ECM components, which can negatively
impact the consistency of feeder-based culture. This would
also limit the ability to interpret differences in the biology
of hPSCs due to undefined determinants contributed by the
feeder microenvironment. Moreover, feeder cells can also
be a source of animal pathogens and mycoplasma contami-
nation. In this regard, Martin et al. showed that most
animal-derived products were a source of the nonhuman
sialic acid Neu5Gc, which get incorporated into hESCs under
standard culture conditions, and the transplantation of the
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Figure 1: Importance of culture media optimization for stem cell engineering.
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of human feeders was therefore proposed as an alternative to
MEFs, in order to prevent the use of nonhuman components.
While feeders from fetal human tissue seem to be the most
supportive, such as feeders from human fetal muscle and skin
[25], fetal foreskin [26], and fetal liver stromal cells [27], the
use of aborted embryos for fetal fibroblast extraction poses
ethical implications. Therefore, several other human cell
types have been tested for their ability to maintain hPSC
pluripotency in culture, including human adult fallopian
tubal fibroblasts, bone marrow cells [28], umbilical cord
[29], placental cells [30, 31], and endometrial cells [32].
Autogenic feeder layers derived from differentiated fibro-
blasts from the hESCs itself were another approach taken
to circumvent the use of donor feeder cells altogether
thereby completely eliminating the risk of allogenic patho-
gen contamination [33, 34]. Despite these innovative
advances, it is important to realize the limitation of feeder
cell-dependent culture systems, mainly owing to their lot-
to-lot variability and inconsistencies between different
culture batches, ultimately making them unsuitable for
therapeutic applications.
2.2. Feeder-Free Culture System. The studies done using dif-
ferent types of feeders, the analysis of the components they
produce in culture, and the comparison between different
feeder types have enabled us to understand the mechanisms
and pathways that are fundamental in maintaining pluripo-
tency. To fully harness the potential of these cells, it is imper-
ative to establish defined culture systems, which can support
large-scale generation of hPSCs and their therapeutic deriva-
tives. Since the derivation of hPSCs, several animal-derived
products have been employed to provide conditions suitable
for maintaining pluripotency and directing them towards
differentiation. Traditionally, hPSCs have been cultured on
a layer of MEFs in media supplemented with fetal bovine/calf
serum (FBS or FCS) and animal-derived growth factors. The
use of animal-derived components, however, raises the possi-
bility of xeno-contamination and immune rejection. Hence,
these culture systems render hPSCs unsuitable for clinical
transplantation. In order to satisfy clinical-grade standards,
culture systems that are completely xeno-free need to be
developed without compromising on hPSC quality and
quantity. Therefore, significant research has been dedicated
to understanding the mechanisms that regulate pluripotency.
This has led to the development of chemically synthesized
xeno-free products and small molecules that allow replace-
ment of all animal-derived components in vitro, while main-
taining suitable culture conditions for pluripotent stem cells.
Approaches to develop feeder-free systems consisted of
identifying a suitable basal medium, as well as a synthetic
substrate/coating which would substitute for the defined
and undefined soluble factors provided by feeders in culture.
For example, Chin et al. identified nearly 30 proteins secreted
by feeders derived from different sources, out of which they
demonstrated the capability of six proteins in supporting
hESC culture [35]. The use of MEF-conditioned media
and animal-derived ECM proteins, specifically Matrigel™
(Corning), which was produced by Engelbreth-Holm-
Swarm mouse sarcoma cells, or laminin, was reported to
stably maintain hESCs for several passages [36]. Since
then, several approaches have aimed at replacing both
MEF-conditioned media with supplements or small mole-
cules and Matrigel with purified recombinant ECM proteins
[22, 37–40]. In the following sections, we discuss the key
components of feeder-free media and their roles, an under-
standing of which is required for the development of chemi-
cally defined media.
Attempts to generate defined media for hPSCs, ensuring
batch-to-batch consistency, have yielded several commer-
cially available options for feeder-free culture, some of which
are xeno-free and some that also comply with cGMP (Cur-
rent Good Manufacturing Practices) (Table 1). Commonly
used commercial media include mTeSR1, TeSR2, TeSR-E8,
RSeT and NaïveCult (STEMCELL Technologies), StemPro,
Essential 8 and StemFlex (Thermo Fisher Scientific), Pluripro
(Cell Guidance Systems), PluriSTEM (Millipore), StemFit
(Ajinomoto), and Nutristem (Corning). Some of these media
such as TeSR2 contain human serum albumin (HSA),
Table 1: Commonly used commercial media for feeder-free culture of hPSCs.
Medium Components Extracellular matrix XF/CD Company
mTeSR™1
DMEM/F12, BSA bFGF, TGFβ, insulin, transferrin,








DMEM/F12, with recombinant HSA, bFGF,
TGFβ, insulin, transferrin, cholesterol, lipids,



























DMEM/F12, HSA Activin A, TGFβ1, bFGF, lipids,
insulin, transferrin, selenium
Not defined XF Millipore
XF: xeno-free; CD: chemically defined medium; NA: not available (neither XF nor CD).
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whereas the more recent and widely used Essential 8
medium, which is derived from TeSR2, does not contain
either HSA or bovine serum albumin (BSA) and was
amongst the first to be considered truly defined media. How-
ever, most commercially available and in-house media con-
tain expensive recombinant growth factor proteins, such as
FGF2 and TGFβ/Activin A/Nodal, at varying concentrations,
the functions of which will be discussed in upcoming
sections.
3. Basic hPSC Culture Media Components
3.1. Basal Media. DMEM/F12 is the standard basal media
used in hPSC culture, and a comparative analysis of 12 differ-
ent base media did not lead to the identification of any other
basal medium which performed better than DMEM/F12
even in serum-free conditions [41]. Apart from glucose,
amino acids, and vitamins, which are components of
DMEM/F12 itself, cholesterol, lipids, insulin, transferrin,
selenium, ascorbic acid, g-aminobutyric acid (GABA), lith-
ium chloride (LiCl), pipecolic acid, and β-mercaptoethanol
(BME) are other components often included in serum-free
culture media. Another component of serum-free media is
L-ascorbic acid-2-phosphate, which has been included in
media compositions as it enhances hPSC survival and prolif-
eration, along with FGF2, as was shown by Furue et al. and
Chen et al. [38, 41]. Cholesterol, another additive, is the
precursor of a steroid hormone and a component of signaling
proteins, due to which it is also included in media composi-
tions [42]. BME which is often added in media to prevent
toxicity from oxygen radicals is itself toxic to cells, and the
presence of BSA in media offsets any detrimental effects from
BME. Chen et al. showed that in the absence of BME, BSA
was no longer necessary for hPSC media [41]. They also
reported the need for selenium in media to support sustained
expansion and transferrin to improve survival and cloning
efficiency [41]. Selenium is also important in culture media
as it has been shown to protect cells against oxidative damage
by optimizing the activity of glutathione peroxidase and
thioredoxin reductase, in addition to stimulating cell growth
and proliferation [43].
3.2. Microenvironment of hPSC Culture. In general, hPSCs
are cultured in normal atmospheric oxygen (21%), although
mammalian preimplantation embryos develop in relatively
hypoxic conditions in vivo, characterized by 1.5-8% oxygen
tension [44]. While hESCs can be maintained reproducibly
at 21% oxygen tension, several studies have provided
evidence that mimicking physiological oxygen levels (~4%)
is beneficial to hESCs by reducing spontaneous differentia-
tion [45, 46] and by upregulation of genes that are known
to support pluripotency of hPSCs, suggesting that some
transcriptional programs in hPSCs are oxygen-sensitive
[47]. In contrast, Chen et al. reported no clear benefit of cul-
turing hESCs in 5% oxygen tension, with respect to morphol-
ogy, survival, and gene expression, as long as a 7-day splitting
interval was maintained [48]. However, others have also
reported that low oxygen tension (2%) enhanced hESC clonal
recovery and decreased the frequency of spontaneous
chromosomal aberrations, without any significant changes
in pluripotent marker expression [49]. Furthermore, it has
also been shown that 2-5% oxygen tension increases hESC
proliferation rate as well as expression of NANOG and
POU5F1, the key pluripotency genes [39, 50]. A recent study
interestingly reported that hypoxia could indeed influence
cell fate decisions in culture, as 2% oxygen alone could
reactivate expression of hESC markers in hPSC-derived dif-
ferentiated cells [51]. These studies show that while hPSCs
can be maintained at atmospheric oxygen tension, it may
be more beneficial to lower the same to 2–5%; however, the
impact is still controversial, and the effects may vary with dif-
ferences in culture media, splitting intervals, and may be cell
line-dependent too.
A study of the physiochemical environment of culture
media showed that hESCs were better maintained when the
basal media had high D-glucose concentration (4.5 g/l) and
an osmolarity that mimicked the natural environment of
embryonic tissue, with optimal performance obtained with
320mOsm [52]. However, the use of 340–350mOsm has also
been reported in the development of TeSR1, mTeSR1, and E8
media [39, 41, 53].
Given the influence that pH has on every biological
process and in maintaining homeostasis in vivo and
in vitro, variations in pH affect several mechanisms within
the cells and their microenvironment. The pH of the culture
media is an important factor involved in maintenance of
hESCs, in the successful reprogramming of somatic cells to
hiPSCs, and in the induction of differentiation of hPSCs. Sev-
eral cellular traits can be affected actively or passively by the
pH, such as the motility, enzymatic activity, cell cycle, and
apoptosis. It also affects cell motility through changes in the
cytoskeletal components [54]. It has also been shown that
upon reprogramming, the colonies obtained when the
culture media was within pH 7.0 to 7.4 showed a compact
morphology with strong alkaline phosphatase activity,
whereas a slight change in pH to 7.6–7.8 made the colony
morphology dispersed and flat. Similarly, when hPSCs were
cultured at different pH values, morphological differences
were observed at each pH, with colonies being more compact
at a pH of 6.8, and as pH increased to 7.8, the cells were more
dispersed and could be observed as single cells.
3.3. Serum Alternatives for hPSC Media. As the use of FBS/
FCS in hESC cultures was a risk factor, other studies used
human serum- (HS-) containing medium and demonstrated
the ability of HS to efficiently maintain hESC pluripotency,
self-renewal, and a stable karyotype for at least over 30
passages [25, 55]. Although this provided an animal-free
alternative, it did not address the issue of undefined serum
compositions and lot-to-lot variation, which could lead to
variability in hPSC culture with respect to their ability to
maintain pluripotency, self-renewal, differential potential,
and a stable karyotype. These made them unsuitable for
downstream therapeutic applications. One of the earliest
attempts to generate a substitute for serum led to the devel-
opment of the proprietary Knockout Serum Replacement
(KSR) [56], now commercially available and used as a
standard in media for hPSCs grown on MEFs. Amit et al.
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showed that the cloning efficiency of hESCs increased by
several folds in the presence of 20% KSR as compared to
serum-containing medium and that hPSCs derived by
serum-containing media could easily be transitioned to
KSR-containing media without any compromise on self-
renewal capacity or pluripotency [26]. The expression
profiles of pluripotency-associated genes were observed to
be similar under FBS-containing and KSR-containing media
formulations [57]. It was also shown that hPSCs exhibited an
increased growth rate when grown in KSR-containing
medium compared to FBS-containing medium [58].
Rajala et al. tested several combinations of culture media
and showed that KSR-containing medium was superior to
HS containing one [59]. Other publications reported the
ability of KSR to efficiently derive hPSC lines thus con-
firming the efficacy of KSR and its compatibility with
hPSC media [30, 60].
Further, enormous efforts have been invested in finding
essential factors in the serum or serum replacement to come
up with a simple and defined culture condition. Supplemen-
tation of DMEM/F12 with N2 and/or B-27, in the presence of
growth factors like bFGF, was shown to support prolonged
self-renewal of hESCs [22, 61]. Replacement of serum and
KSR with albumin, specifically HSA and BSA, in TeSR1
[39] and mTeSR1 [53], respectively, has also been widely
used for hPSC cultivation. Interestingly, the addition of
0.1% HSA reportedly rescued the loss in hPSC viability
caused by insulin depletion in suspension-grown hPSCs, thus
demonstrating the diverse ways in which albumin can
support hPSC pluripotency and viability in culture [62].
Another serum replacement product, lipid-rich BSA, known
as AlbuMAX, was identified as the active ingredient and pre-
dominant lipid source in KSR [63]. It is a mixture of albumin
with lipids (such as cholesterol, phospholipids, and triacyl-
glycerides) and free fatty acids (alpha-linolenic acid, linoleic
acid, oleic acid, stearic acid, and palmitic acid) [64]. It was
shown that hESCs could be stably maintained in KSR-
deficient media supplemented with 1% AlbuMAX and N2/
B27, thus achieving a more defined media composition
[63]. Another study showed how supplementation of chemi-
cally defined media (CDM) such as E8, with AlbuMAX,
reduced the alterations in metabolic flux that are usually
induced upon culture in CDM such as E8 [65]. Indeed, most
serum replacements include albumin (such as BSA/HSA), as
it is the most abundant protein in serum. The addition of
albumin helps in protecting the cellular surface and stabiliz-
ing other proteins in the culture media, making it a beneficial
additive in serum-free media. However, it is not an absolute
requirement in hPSC media, as the commercially available
media E8 does not include any albumin [41]. In this regard,
Chen et al. and Yasuda et al. reported that in the absence of
any serum replacement, insulin and transferrin are the two
minimum required proteins in addition to growth factors
and chemical compounds [41, 66]. Moreover, the purifica-
tion of albumin from serum or culture supernatants (in the
case of recombinant protein expression) can introduce con-
taminants, owing to albumin’s high capacity of binding
proteins, ions, chemicals, and pathogens, which are difficult
to get rid of upon purification. Further studies are required
to elucidate the precise roles and mechanisms by which these
proteins in serum replacements maintain pluripotency and
self-renewal, so that they can be replaced by defined and
cost-effective chemical compounds, which could possibly
make serum replacements obsolete in the future.
4. Growth Factors for hPSC Culture
4.1. Fibroblast Growth Factors (FGFs). Along with KSR, the
earliest identified component that was found to contribute
to stem cell pluripotency and self-renewal was basic fibro-
blast growth factor (bFGF or FGF2), which was shown to
be endogenously produced by human feeder layers in hESC
cultures [27, 43]. It was found that FGF2 was indispensable
for maintaining undifferentiated proliferation of ES cells in
KSR-based media [26]. Xu et al. also reported that FGF2
was essential to support undifferentiated hESC growth in
serum replacement media, alone or in combination with
other growth factors in the absence of feeders or conditioned
media, while maintaining comparable morphology, surface
marker and transcription factor expressions, karyotype,
telomerase activity, and differentiation potential [67]. In
feeder-free systems, it has been shown that FGF2 at a range
of concentrations (4 to 100ng/ml) was required to sustain
the pluripotency of hPSCs over several passages, equivalent
to conditioned media from MEFs [68]. FGF2 was found to
stimulate the secretion of supportive factors from MEFs
which reduced differentiation-inducing activity, and it regu-
lated the expression of TGFβ family members, enabling them
to act on hPSCs in an autocrine way to promote self-renewal
[69]. cDNA microarray analyses of hESCs compared to
mESCs and differentiated human cells showed the enrich-
ment of FGF2/13 and FGFR1, 2, and 4 in PSCs [70–72].
Another group validated this with real-time PCR results con-
firming that FGFR1-4 were indeed expressed in hESCs with
FGFR1 being the most abundant [73], while Eiselleova et al.
reported that FGF2 dominantly signaled via FGFR2 [74].
Furthermore, addition of the FGFR inhibitor SU5402 led to
rapid cell differentiation by suppressing the activation of
downstream protein kinases and downregulating OCT3/4,
thus suggesting the existence of autocrine FGF signaling in
hPSC cultures [73]. Consistent with this, another report
showed that the knockdown of FGF2 led to rapid differenti-
ation in hPSCs, and the undifferentiated phenotype could
not be rescued by the addition of exogenous FGF2 either.
Instead, exogenous FGF2 functioned to reinforce the pluri-
potency maintenance program of intracrine FGF2 signaling
[74]. Altogether, FGF2 promotes hPSC self-renewal and pro-
liferation in the undifferentiated state in several ways. It binds
to FGFR and activates the cascade of the mitogen-activated
protein kinase (MAPK) pathway, as well as the phosphatidy-
linositide 3-kinases (PI3-kinase)/AKT pathway, leading to
high basal levels of extracellular signal-regulated kinases
(ERK) 1/2 and protein kinase B (PKB)/AKT, respectively,
in hPSCs, both of which are implicated in the expression of
stem cell genes and suppression of cell death and apoptosis
genes [73–75]. This was confirmed by Li et al. who also
showed that both mitogen-activated protein kinase (MEK)/
ERK and PI3K/AKT signalings were downstream targets of
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the FGF pathway, as shown by high levels of phosphorylated
MEKs, ERKs, and PKB/AKT, upon FGF2 treatment of hESCs
[75]. Interestingly, while the inhibition of MEK/ERK and
PI3K/AKT alone or together led to the rapid loss of self-
renewal capacity in hPSCs, the inhibition of only PI3K/
AKT led to a significant decrease in cell proliferation and a
marked increase in apoptosis, thus suggesting both common
and distinct roles of these two pathways downstream of FGF
signaling in hPSCs [75]. In another study, it was also shown
that neurotrophins (brain-derived neurotrophic factor, neu-
rotrophin 3, and neurotrophin 4) improve hESC survival sig-
nificantly, and this effect is mediated by the PI3K pathway
but not the MEK/ERK pathway [76].
As mentioned above, the MEK/ERK pathway is known as
one of FGF target pathways in hPSCs. Kang et al. were
amongst the first to report that FGF signaling in hESCs
induced the activation of ERK (extracellular signal-
regulated kinase), which in turn induced expression of c-
fos, an early downstream target of the MEK/ERK1/2 pathway
[77]. It was shown that MEK/ERK inhibition in hESCs by
specific MEK inhibitors PD98059 and U0126, or by RNA
interference, rapidly caused the loss of the undifferentiated
state; however, it did not affect cell proliferation or survival,
while PI3K/AKT inhibition by LY294002 induced a signifi-
cant decrease in cell proliferation and increase in apoptosis
[75]. These data suggest that in response to FGF, the MEK/
ERK pathway supports hPSC self-renewal in cooperation
with other pathways such as the PI3K/AKT pathway. The
physiological role and targets of MEK/ERK in hPSCs have
not yet been clarified and need to be determined. However,
as a common effector downstream of both platelet-derived
growth factor (PDGF) and FGF, MEK/ERK seems to be cru-
cial for supporting pluripotency-related processes regulated
by receptor tyrosine kinases (RTKs).
Heparin and heparan sulfate proteoglycans form high-
affinity binding complexes with FGFs and are therefore
included in media to control the activity and stability of FGFs
[78]. Furue et al. showed that the addition of heparin also
promoted hESC proliferation in the absence of FGF2 in a
dose-dependent manner [38]. Heparin induced expression
of cyclin D1, a cell cycle regulator, and also rapid phosphor-
ylation of the FGF receptors in hESCs, in the absence of
exogenous FGF2, suggesting that it helps hPSCs in stabilizing
endogenously produced FGF [38]. In addition, heparin has
also been found to enhance the activity of Wnt and FGF
signalings in hESCs [79].
4.2. Other Ligands of Receptor Tyrosine Kinases (RTKs). A
proteomic screen of MEF-conditioned media aimed at
identifying candidate growth factors that support hESCs in
culture showed that insulin-like growth factor (IGF), specifi-
cally IGFII, was the most abundant [80]. It has been shown
previously that autologous feeder layers derived from sponta-
neous differentiation of hESCs into fibroblasts supported the
growth of pluripotent hESCs, and these fibroblast-like differ-
entiated hESCs expressed a higher level of FGF receptors
than the undifferentiated hESCs in the same culture dish
[34]. Under such culture conditions, treatment with FGF2
led to the release of IGFII and TGFβ factors from the
autologous feeder cells which then acted upon the undifferen-
tiated hESCs in a paracrine manner to promote self-renewal
and pluripotency [80]. They reported that undifferentiated
hESCs expressed IGF1 receptor RTK (IGF1R) which, when
blocked, reduced survival and clonogenicity of hESCs, while
the surrounding feeder cells expressed FGFR1 which, when
blocked, led to differentiation. Their results suggested that
IGFII alone could sustain hPSC growth and expansion in
long-term culture, and its IGF signaling was mediated via
activation of the PI3K/AKT pathway [80]. The importance
of insulin in hPSC media was also confirmed by Wang et al.
who showed that the IGF1R blocking antibody reduced hESC
proliferation and induced differentiation, and moreover,
IGF1R-specific shRNA transduced in hESCs was incapable
of self-renewal in culture [81]. Other studies aimed at
identifying specific factors in serum that promote the
growth of hESCs showed that the lysophospholipid sphin-
gosine 1-phosphate (S1P), together with PDGF, needs to
be present to maintain hESCs in their undifferentiated
state in feeder-free culture and that S1P and PDGF have
an antiapoptotic effect in hESCs [82, 83]. Phosphoproteomic
analysis of hESCs also revealed that the PDGF receptor RTK
(PDGFR) inhibitor led to differentiation of hESCs and a
decrease in expression of pluripotency markers. PDGF-AA
cooperated with bFGF to stably maintain undifferentiated
hESCs in culture, and it helped preserve their undifferen-
tiated state even under suboptimal concentrations of
FGF2 [84].
Furthermore, the role of RTK signaling was demon-
strated in another study that investigated the contribution
of epidermal growth factor receptor (EGFR) family mem-
bers, in hESC culture. They found that the ERBB2/3 was
expressed on hESC cells thus implying a role for its ligand
neuregulin 1 (NRG1) [81]. Furthermore, inhibition of ERBB2
significantly reduced hESC proliferation and induced
apoptosis in feeder-free cultures [81]. Taking into account
the roles of these identified growth factors,Wang et al. assem-
bled a simple feeder-, serum-, and KSR-free defined medium
(DC-HAIF), designed to stimulate IGF1R and ERBB2/3 sig-
nalings, by incorporating neuregulin 1 (or heregulin-1β),
FGF2, LR3-IGF1 (a GMP-grade recombinant human IGF1),
and Activin A [81]. They showed that hESCs could be
successfully and stably propagated in this media for several
months with minimal spontaneous differentiation.
4.3. TGFβ Superfamily. The TGFβ superfamily consists of
over 100 proteins, including the TGFβ proteins, Activin,
Nodal, bone morphogenetic proteins (BMPs), and growth
and differentiation factors (GDFs), all of which mediate sev-
eral biological effects through receptor serine/threonine
kinases, to maintain stem cell fate. Once activated by binding
of TGFβ family ligands, these receptors phosphorylate and
activate Smad proteins, which translocate to the nucleus,
and function as transcriptional cofactors to activate target
genes. Type I receptors (TGFRI), also termed Activin-like
kinases (ALKs), play a central role in pluripotency, as BMP
ligands and Activin/Nodal/TGFβ ligands exert their effects
through receptor ALK 2/3/6 (activating SMAD 1/5/8) and
ALK 4/5/7 (activating SMAD 2/3), respectively [85].
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The effect of eight different growth factors on the differ-
entiation of hESCs was evaluated by Schuldiner et al. wherein
TGFβ1 did not lead to the production of transcripts in differ-
entiated cells, thus suggesting its role in the repression of
hPSC differentiation. Amit et al. showed that TGFβ1 contrib-
uted to a cocktail of growth factors that also included FGF2,
to maintain the undifferentiated state of hESCs in feeder-free
culture [37, 86]. It was reported that in undifferentiated cells,
the TGFβ/Activin/Nodal branch was activated through the
signal transducer SMAD2/3 which was achieved by addition
of Activin A (25 ng/ml), and this was shown to be required
downstream of canonical Wnt activation, which was neces-
sary to maintain hPSCs [87–89]. This dependence was
further confirmed by studies which showed that TGFβ/Acti-
vin/Nodal-responsive SMAD2/3 directly binds to the Nanog
proximal promoter and activates its expression [90]. The
requirement of Activin/Nodal signaling through SMAD2/3
activation for maintaining pluripotency was confirmed by
another study as well [88], wherein inhibitors of this signal-
ing pathway led to hPSC differentiation. However, according
to this study, neither Nodal nor Activin alone was capable of
sustaining long-term hPSC growth, but either of these, when
combined with FGF2, helped achieve the optimal conditions
for maintaining long-term hPSC pluripotency and self-
renewal [88]. This was in agreement with Xu et al. who also
showed that either FGF or TGFβ alone was incapable of
maintaining long-term pluripotency of hESCs [91].
While Nodal and Activin A act on the same receptors and
activate the same signaling mechanisms to suppress hPSC
differentiation [87–89], the latter is used more often in vitro
for cell culture due to its wider availability as a recombinant
protein and comparatively lower cost. Beattie et al. also
showed that Activin A was secreted by MEF feeders and
enriching the culture medium with a combination of exoge-
nous Activin A (optimum concentration determined to be
50 ng/ml), along with FGF7 (keratinocyte growth factor,
50 ng/ml) and nicotinamide (10mM), maintained hESCs in
an undifferentiated state for over 20 passages without MEF
feeders or conditioned medium [92]. Removal of Activin A
on the contrary led to rapid differentiation of hPSCs thereby
confirming the inevitability of this growth factor in hPSC
culture media [92]. A detailed study by Xiao et al. provided
evidence for the first time that low concentrations of Activin
A (5 ng/ml) was necessary and sufficient to support undiffer-
entiated hESC growth on feeder-free culture (Matrigel) [40].
They also showed that Activin A induced the expression
of OCT4, Nanog, Nodal, Wnt3, and FGF2 and suppressed
the BMP signal, thereby reflecting its central role in
maintenance of hPSC pluripotency and self-renewal [40].
Interestingly, however, Activin A has paradoxical effects
on hPSCs in both maintenance of pluripotency and induc-
tion of differentiation, as Activin A-induced differentiation
of hPSCs into mesoendodermal cells is well documented,
wherein studies suggest that higher concentrations induce
differentiation while lower concentrations are necessary
for pluripotency [86, 93].
Another member of the TGFβ superfamily, BMP4, which
is known to synergize with leukemia inhibitory factor (LIF)
to maintain pluripotency in mESCs, has an opposite role in
hPSCs. While BMP signaling maintains self-renewal in
mESCs, it induces differentiation in hPSCs [94]. This was
revealed through reports which showed that hESCs, grown
in serum-free media supplemented with FGF2, were induced
by BMP4 to differentiate into a different extraembryonic
lineage, the trophoblast [95], or spontaneously differentiate
into extraembryonic endoderm-like cells due to BMP2 [96].
This was confirmed by other studies in which the addition
of BMP4 in the medium induced a rapid loss of pluripotency
in hESCs [92], and the BMP4 antagonist Noggin (500 ng/ml)
had a synergistic effect with FGF2 (40 ng/ml) in maintaining
the undifferentiated state of hESCs [67, 97]. The latter group
showed that BMP2 and BMP4 proteins were detected at
higher levels in serum replacement-based hESC cultures, as
compared to MEF-conditioned media-based cultures, which
could be repressed by either a combination of Noggin and
FGF2 or a high dose of FGF2 (100 ng/ml), both of which sus-
tained long-term undifferentiated proliferation of hPSCs in
feeder-free culture condition [67]. Xu et al. also showed that
both TGFβ and FGF signalings synergize to antagonize BMP
signaling, thereby sustaining expression of genes associated
with pluripotency, such as NANOG, OCT4, and SOX2
[91]. Dorsomorphin, another small molecule included in
some xeno-free media compositions, acts by inhibiting
BMP signaling thereby promoting hPSC self-renewal and
preventing BMP-induced differentiation in hPSCs [98, 99].
4.4. Wnt Family. Wnt signaling has been implicated in
numerous functions in stem cells, and in general, they act
to maintain stem cells in their undifferentiated state. Sato
et al. showed that the activation of the canonical Wnt path-
way was sufficient to maintain the self-renewal capacity of
hESCs [71]. They reported that Wnt activation by inhibition
of glycogen synthase kinase-3 (GSK-3) or addition of recom-
binantWnt3a in the media promoted the growth of compact,
undifferentiated hESC colonies, compared to nontreated
cells. Furthermore, withdrawal of the GSK-3 inhibitor led
to reversal of the pluripotent state and induced differentia-
tion [71]. Dravid et al. on the other hand, reported that
Wnt activation was not sufficient to maintain the pluripotent
state of hESCs, but Wnt3a application stimulated hESC pro-
liferation instead [100]. Cai et al. also showed that if FGF2 or
MEF-conditioned media- (MEF-CM-) derived factors were
absent, addition ofWnt3a orWnt1 stimulated hESC prolifer-
ation and also differentiation [101]. In the presence of FGF2
and MEF-CM, however, Wnt can stimulate proliferation of
the undifferentiated hESCs [101]. A meta-analysis of
microarray data identified the Wnt receptor FZD7 to be a
hESC-specific antigen, which upon knockdown led to a rapid
change in morphology of cells and loss of expression of
pluripotency markers, thereby suggesting the contribution
of Wnt signaling to the pluripotency and self-renewal capac-
ity of hPSCs [102]. Wnt activation in media can be achieved
by using chemical GSK-3 inhibitors, which are, in increas-
ing order of specificity, lithium chloride, 6-bromoindiru-
bin-3′-oxime (BIO), and CHIR99021, thus eliminating
the need for any xenogenic compounds for modulating
Wnt signaling [103, 104]. In another study, Hasegawa
et al. identified a small molecule Wnt signaling modulator,
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ID-8, which along with Wnt3a completely prevented Wnt-
induced differentiation without affecting proliferation and
while maintaining stable hPSC survival as well [105].
Therefore, although the role of Wnt/β-catenin signaling
in hPSCs is unclear and there is no consensus regarding
its effect on self-renewal or differentiation, the above stud-
ies highlight how FGF2, Wnt, and TGFβ signalings collab-
orate to maintain hPSC self-renewal, pluripotency, and
proliferation in vitro. In another study, it was reported
that Wnt3a and FGF alone were not capable of supporting
hPSC growth on feeder-free systems, but with the addition
of insulin, transferrin, albumin, chemically defined choles-
terol, and a proliferation-inducing ligand (April)/B cell-
activating factor belonging to TNF (BAFF), a modified
medium named HESCO was developed which was able
to support hESC proliferation and self-renewal for over
three passages [42]. Interestingly, Tsutsui et al. developed
a defined culture system wherein a unique combination
of molecules including bFGF, along with inhibitors against
GSK, MEK, and Rho-associated kinases (ROCK), allowed
long-term maintenance of hESCs through single cell
passaging [106].
Recent studies have shown that Wnt/β-catenin signaling
is active in the naïve state of pluripotency in hPSCs, while it is
reduced or absent in the primed state. Naïve hPSCs secrete
Wnts that activate Wnt/β-catenin signaling in an autocrine
or paracrine manner, which promote efficient self-renewal
and inhibit their transition to a primed state [107]. Inhibition
of Wnt/b-catenin signaling in naïve hPSCs does not lead to
differentiation, and the cells continue to express stem cell
markers. Also, it induces transition towards primed like
hPSC state [107].
5. Chemical Compounds
Over the past two decades, majority of hPSCs have been
maintained in culture including xenobiotic components
which carry a risk of contamination of immunogens or
pathogens rendering those cells incompetent for regenera-
tive medicine applications. Hence, the development of
chemically defined or xeno-free systems for the hPSC culture
system is necessary. To circumvent these challenges
researchers have been putting efforts to develop defined con-
ditions for hPSCs by using chemically synthesized molecules
which regulate a biological process. Chemical compounds
such as MEK inhibitors (PD98059 and PD0325901), GSK-3
inhibitors (Wnt signal activator) (BIO and CHIR99021),
Rho-associated kinase (ROCK) inhibitor (Y-27632), FGF/
RTK inhibitor (PD173074), and TGFβ/ALK inhibitor
(SB431542) are commercially available and most widely used
for the maintenance, proliferation, and differentiation of
hPSCs. Since FGFs/RTKs, TGFβs/ALKs, and Wnts/GSK-3
signaling have been described in previous chapters, com-
pounds widely used for regulating other signaling in hPSCs
will be reviewed in this chapter.
5.1. ROCK Inhibitor. Rho-associated protein kinase
(ROCK), a downstream effector of Ras homolog gene
family member A (RhoA), is a kinase belonging to the
family of serine/threonine kinases and is involved mainly
in regulating the shape and movement of cells by acting
on the cytoskeleton [108]. Poor viability of hPSCs during
passage caused by apoptosis, due to actomyosin hyperacti-
vation called blebbing [109], is an obstacle to researchers,
hampering daily routine culture such as dissociation/
expansion. ROCK inhibitors such as Y-27632 reduce this
blebbing and minimize apoptosis, thereby enhancing the
cloning efficiency after cell dissociation [110]. Studies have
also shown that the ROCK inhibitor enhances the effi-
ciency and survivability of hPSCs after freeze-thaw cycles
[111, 112]. It also helps to keep hPSCs in an undifferenti-
ated state in feeder as well as feeder-free conditions [113].
In the absence of ROCK inhibition, apoptosis can be
reduced by dissociating hPSCs as cell clumps instead of
single cells, while ROCK inhibitor addition at the time of
passage can partially reduce the apoptosis induced during
single cell dissociation. Therefore, further studies highlight-
ing methods for reducing stress induced by dissociation
into single cells even further are required for achieving
maximum viability.
5.2. Compounds Used for Naïve Culture Condition. Initial
attempts to derive or maintain naïve hESCs relied on the
continuous ectopic expression of pluripotency genes in
addition to hPSC media containing leukemia inhibitory
factor (LIF) and inhibitors of both MEK and GSK-3 (termed
2i) [114–116]. However, recently, Gafni et al. developed a
chemically defined media called naïve human stem cell
medium (NHSM), which contained a basal media of
DMEM+KSR, N2, AlbuMAX and insulin, and growth
factors FGF2 and TGFβ, supplemented with 2i/LIF
(described above), p38/MAPK inhibitor (SB203580), and
the noncanonical Wnt/c-Jun-N-terminal kinase (JNK)
inhibitor (SP600125), which was further optimized to
improve cell viability by addition of the ROCK inhibitor
(Y-27632) and protein kinase C (PKC) inhibitor (Gö6983)
[13]. Other studies have shown, however, that minimal
media consisting of bFGF, with MEK and GSK inhibitors
[15], or additionally with the ROCK inhibitor and LIF
[117] can support naïve pluripotency. Interestingly, [118]
showed that a different cocktail of 5 inhibitors (5i) including
inhibitors of MEK (PD98059), GSK (IM12), ROCK (Y-
27632), BRAF (SB590885), and LCK/SRC (WH-4-023)
along with LIF, bFGF, and Activin A (5i/L/F/A) was the
most efficient for derivation and maintenance of naïve
hPSCs. They also showed that inclusion of 20% KSR was
detrimental to induction of naïve pluripotency, compared
with culture in N2/B27 media, as well as supplementation
with the GSK inhibitor (CHIR99021) was tricky because
lower concentrations improved the maintenance of naïve
pluripotency, while higher concentrations led to the oppo-
site. The reduction in CHIR99021 concentration to 1μM
also cooperated well with MEK and PKC inhibitions, in
the presence of LIF (termed t2iL+Go) for maintaining
naïve pluripotency [119]. Interestingly, a recent report has
shown that Wnt5A is a crucial component which, together
with 2i/LIF and bFGF, promotes induction of naïve pluripo-
tency in established hESC lines [120].
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6. Extracellular Matrices
The knowledge of feeders and an understanding of the cross-
talk between ECM components, cells, and media have been
exploited to develop feeder-free extracellular matrices
(ECMs) which mimic the conditions that feeders provided,
for hPSCs while reducing the dependency on xenogeneic
components. As mentioned earlier, one of the first substrates
used as a feeder-free alternative was Matrigel, which is
mainly composed of attachment proteins like laminin,
entactin, collagen IV, and heparan sulfate proteoglycans, in
addition to growth factors, and each of these individual com-
ponents show varying levels of efficiency in supporting hPSC
culture [36]. However, since Matrigel is derived from an ani-
mal source, it can introduce unwanted xenogeneic contami-
nants too, thus making this unsuitable for clinical therapies.
Significant progress has been made in identifying individual
ECM components such as laminin-511, fibronectin, and
vitronectin in the hope of developing chemically defined
and synthetic substrates. Laminin-coated surfaces are very
efficient in supporting the pluripotency and proliferation of
hPSCs, while collagen IV and fibronectin are not [36]. Fur-
thermore, specific laminin isoforms show different effects as
ECM substrate with isoforms -111, -332, and -511, but not
-211 and -411, being able to support the attachment and pro-
liferation of undifferentiated hPSCs. In addition, it has been
shown that supportive feeder cells and hPSCs produce lami-
nin isoforms -511/-521 and express the integrin α6β1 recep-
tor, the primary receptor for these laminin isoforms [121].
Since integrins are the principal molecules that mediate
cell-ECM interactions, other substrates such as vitronectin,
which has been shown to support hPSC self-renewal via
integrin αVβ519, have been developed [122]. Recombinant
human laminin-511 and -521, vitronectin and E-cadherin,
and their short fragments were amongst the first defined
ECM substrates to be described, and they have now been rou-
tinely employed in feeder-free culture. Their use therefore
represents an important milestone in hPSC culture. These
led to the development of polymers, modified with synthetic
peptides, such as SyntheMax [123]. However, the exact
mechanisms of cell-ECM and cell-cell adhesion in hPSCs
are still not clear and need to be addressed.
7. hPSC Bulk Culture Systems
For applications in engineering and medicine, hPSCs need to
be generated in quantities of 1010 cells or more, while also
adhering to cGMP guidelines and the requirements of regu-
lations governing hPSC-based therapeutics [124, 125]. 2D
adherent feeder-free culture can be “scaled-out” by multiply-
ing the culture volume through the use of multilayered flasks,
and some robotic platforms that can automate the process
have been shown to provide large-scale quality-controlled
manufacture of hPSCs [126, 127]. However, this method of
bulk culture is still limited for commercial use by require-
ments of considerable space, time, cost, and operators, while
also restricting online monitoring of culture parameters. This
can considerably affect the reproducibility and stability of the
cells in culture. Three dimensional (3D) or suspension
culture in spinner flasks or Erlenmeyer flasks has been
reported for bulk expansion of hPSCs [128–131], while their
volume, control of culture parameters, and monitoring sys-
tem may not be sufficient for hPSC applications that require
large-scale production of hPSCs. Thus, bioreactors providing
control over the culture environment and real-time monitor-
ing of the system parameters need to be developed for indus-
trial level expansion of hPSCs. In these 3D suspension culture
systems, cells are cultured in the form of matrix-free hPSC
clumps as aggregates or as hPSCs immobilized on microcar-
riers or by microencapsulation of the hPSCs. Importantly,
the media used for such large-scale 3D expansion of hPSCs
are based on the culture media used in 2D feeder-free systems
itself, such as KSR-based media, mTeSR1, StemPro hESC
SFM, and Essential 8. Defined protocols for hPSC suspension
culture in mTeSR1 medium have been published and have
been widely used [132, 133]. However, hPSCs cultured suc-
cessfully in 2D systems in certain media may not continue
to behave in the same way when cultured in the same media,
in 3D suspension. This could be because certain media com-
ponents may not remain stable in suspension, as shown by a
recent study, where insulin was found to precipitate from
commercial hPSC media (E8, TeSR-E8, mTeSR1, and Stem-
MAXs iPS-Brew XF), only when used in a peristaltic pump
circuit suspension system [62]. Interestingly, the depletion
of insulin from culture media led to excessive disintegration
of hPSC aggregates with subsequent loss of viability in the
applied culture system, while the omission of bFGF, TGFβ1,
or transferrin did not significantly hamper the morphology
and viability of hPSCs. This showed how insulin was an abso-
lute necessity for hPSC maintenance [62]. Studies such as
these highlight how necessary it is to closely monitor media
components while establishing automated bulk culture sys-
tems. In an interesting report by Lipsitz et al., it has been
shown that the conversion of hPSCs from a primed to an
alternative naïve-like state is advantageous for suspension-
grown hPSCs and shifts them to a high-yield state [134].
They reported that for dynamic suspension cultures, the
use of media supplemented with LIF, TGFβ1, and FGF2,
including inhibitors of GSK-3 (CHIR99021), JNK
(SP600125), p38/MAPK (BIRB796), and PKC (Gö6983),
was the most efficient in supporting a faster growth rate
and higher densities, compared to conventional hPSC media.
Furthermore, they showed that the conversion of primed
hPSCs to this alternative “high-suspension-yield” state in
adherent culture required the MEK inhibitor (PD0325901)
in addition to the above 4 inhibitors, following which when
cells were transferred to suspension culture, it was essential
to withdraw MEK/ERK inhibition, in order to maintain plur-
ipotency. This shows how our understanding of the role of
media components at each stage of the process can enable
more efficient and cost-effective manufacturing of hPSCs
for therapeutic applications. Overall, this system demon-
strated how cell-state conversion induced by specific media
components provided a strategy for long-term, high-density
expansion of hPSCs, in scalable suspension cultures. This
emphasizes the importance of culture media optimization
to overcome the challenge of the low yield of hPSCs in sus-
pension bioreactors [134].
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These 3D culture systems usually consist of biomaterials
to mimic the in vivo microenvironment and 3D niche much
better than 2D systems. These biomaterials contribute to
signaling within the culture and improve cellular crosstalk,
thereby simulating the biophysical and biochemical proper-
ties of the native cellular niche. Therefore, such culture
systems can be used to study embryogenesis and organogen-
esis as well as for drug toxicity and screening assays. It is
worth noting that such scalable hPSC suspension cultures
can also be used as a convenient starting point for inducing
them to differentiate by changing hPSC expansion media to
lineage-specific media [135–137]. Thus, 3D cultivation of
hPSCs in bioreactors allows mass and automated production
of hPSCs and their differentiated cells. Indeed, recent devel-
opments in stem cell research have led to the establishment
of protocols using which hPSCs can be differentiated in sus-
pension to various cell types and hence grown into minior-
gans, termed “organoids.” Organoid cultures are structures
composed of thousands of cells, often coming from different
lineages (that make up an organ in vivo), which self-assemble
themselves into 3D structures, in the presence or absence of
exogenous ECM substrates. This creates a dynamic microen-
vironment between the self-renewing and differentiating
cells, providing the closest in vitro equivalent of the architec-
ture of real organs. They exhibit increased functionality com-
pared to 2D-differentiated cells and thus have wide-ranging
applications in research and the clinic [138].
Various vessels and bioreactors are available for the
hPSC scale-up culture system, such as the stirred tank, air-
lift, spinner flasks, wave-rocking, rotating wall, hollow fiber,
multiplate, magnetic microcarrier, and 3D scaffold bioreac-
tor. They consist of a glass or plastic vessel equipped with
or without an impeller that ensures a homogenous growth
environment by efficient mixing of the cells, nutrients, and
gases, while maintaining an uplift against gravity, to keep
cell aggregates or microcarriers in suspension [139, 140].
hPSCs can be inoculated as single cells or aggregates, with
single cell inoculation, using the ROCK inhibitor, being bet-
ter at preventing extensively large-sized aggregates that can
limit nutrient diffusion [141]. Nutrient feeding can be car-
ried out in batches or by perfusion, although the latter is
reported to result in a more uniform environment enabling
superior cell densities and yields [142]. The key parameters
such as pH, dissolved oxygen (DO) levels, fluid shear stress,
growth factors, nutrients, and metabolite concentrations in
hPSC scale-up culture are precisely and carefully controlled
to ensure a uniform environment with adequate nutrient
levels and oxygenation [129].
Using coated microcarrier beads in bioreactors can be
considered as a practical option. Several studies have demon-
strated that using microcarriers such as polystyrene coated
with laminin and vitronectin, vitronectin and HSA further
treated with UV, or those that are positively charged with
cellulose achieve high attachment efficiencies and viability
even at the high confluency, while also reducing consump-
tion of media and growth factors owing to their adjustable
growth surface area [143–146]. Beads with multiple pores
give a much larger surface area for cell adhesion and gas
diffusion, than flat 2D culture, while the adherent hPSCs
on/in the beads may be very similar to what is obtained in
traditional 2D culture [147]. Lastly, microencapsulation of
hPSCs in hydrogels, such as calcium alginate capsules, has
been developed as a technique to minimize excessive clump-
ing in suspension culture, as well as improve cell recovery
rates after cryopreservation [148]. Although this method
offers increased cell protection, it is limited by reduced diffu-
sion of gases and nutrients through the capsule, plus the
requirement of decapsulation for cell harvest. Thus, 3D cell
culture systems can offer substantial benefits for hPSC cul-
ture and are an attractive platform for manufacture of cellu-
lar products, due to their scalability, ease of monitoring, and
convenient cell feeding and harvesting options. However,
certain important issues, such as controlling growth rate,
aggregate size, differentiation pressure, and ensuring geno-
mic stability, need to be addressed before they can be
approved for clinical applications [149].
8. Conclusion
The growth and advancement in the applications of hESC/
hiPSC technology have been accompanied by a huge body
of work dedicated to optimizing and standardizing hPSC cul-
ture. Optimization of culture systems is not only limited to
defining culture media components but also the extracellular
matrices, environmental cues, and modes of passaging. As
discussed above, this has led to the development of simple
and defined culture conditions and also facilitated the devel-
opment of 3D and bulk cell culture systems. Chemically
defined media are ideal for minimizing lot-to-lot variation
and ensure consistency, for both research-based and clinical
applications, while xeno-free and cGMP-compliant culture
systems are preferred for cellular transplantation. Efforts in
this direction have largely focused on understanding the sig-
naling molecules required, replacing nonhuman components
of media and developing synthetic substrates, which have an
immediate application in disease modelling and can eventu-
ally be used to engineer cells and their substrates for thera-
peutic applications.
The recent findings about the isolation and maintenance
of naïve hPSCs have given immense insight into early human
development, but it is yet to be determined how relevant these
different states of pluripotency are, with respect to down-
stream engineering applications in research and therapy. As
such, future platforms should ideally attempt to be adaptable
for the bioprocessing of both naïve and primed hPSCs.
With stem cell therapies becoming a reality, through the
approval of human trials, preventing any alterations in the
cellular state and identity is of paramount importance. As
new therapies emerge, questions about the safety and efficacy
of the cellular products will also rise. Studies have revealed
the heterogeneity of hPSCs in culture, and some procedures
to isolate and propagate homogenous hPSC clones have been
described. Nevertheless, clearer and more stringent regula-
tions need to define how to maintain cellular homogeneity
in scalable culture systems. It is important to note that one
of the obstacles in the implantation of hPSC-based therapies
is the risk of tumorigenicity, owing to the intrinsic properties
of unlimited self-renewal and expansion of hPSCs. However,
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in addition to the in vivo effects, prolonged periods of in vitro
expansion required for cell therapy itself can lead to stochas-
tic generation of chromosomal aberrations which can then
accumulate rapidly through positive selection pressure. Such
culture adaptations by cells precede the highly undesirable
build-up of gross genomic abnormalities, characteristic of
certain high passage number hPSC lines. Therefore, along
with the establishment of bulk culture systems, the validation
of assays that can efficiently and reproducibly monitor
growth conditions, cellular stress, spontaneous differentia-
tion signals, gene expression profiles, and chromosomal
integrity during production, processing, and storage of
hPSCs is absolutely vital to the success of all downstream
applications. Future research should address these challenges
by establishing protocols for providing robust, stable, and
homogenous cell populations as raw material.
Another potential challenge lies in determining the long-
term effects of major media used for propagation of hPSCs in
large-scale culture systems and addressing the costs associ-
ated with maintenance of these systems. The economics of
hPSC processing are as important to address, as are the con-
cerns with their safety and functionality in patients. Costs
associated with media components have been largely reduced
with an improved understanding of their functions and the
subsequent discovery of small molecules which can substitute
for the expensive growth factors and cytokines, as discussed
above. Apart from making media cost-effective, it has also
led to the media being more defined, hence increasing their
reproducibility.
There are now multidisciplinary approaches available for
the derivation and culture of different stages of pluripotency,
development of xeno-free culture conditions as well as the
generation of GMP-compatible protocols, which would help
standardize and streamline the process on a commercial
scale. The amalgamation of 3D culture systems, chemically
defined media, and synthetic biomaterials mimicking ECMs
shows enormous potential in improving propagation, safety,
and functionality of stem cells for various applications.
The derivation and maintenance of the raw material,
hPSCs, including both hESCs and hiPSCs, have to be done
in a manner that recapitulates their equivalent niche
in vivo; therefore, the media in which these cells are cultured
in are central to the success of all downstream applications.
Therefore, as a starting point, it is necessary to understand
the media components and their roles in regulating the self-
renewal, proliferation, survival, stability, and functionality
of hPSCs as this is a critical step in ensuring large-scale, safe,
reproducible, and quality-controlled expansion of hPSCs for
use in stem cell engineering.
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